Crossmark

Concise informed consent to increase data and biospecimen access may accelerate innovative Alzheimer's disease treatments

Crossref DOI link: https://doi.org/10.1016/j.trci.2017.08.003

Published Online: 2017-09

Published Print: 2017-11

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Hake, Ann M.

Dacks, Penny A.

Arnerić, Stephen P.

,
Funding

Funding for this research was provided by:

U.S. Food and Drug Administration (1U18FD005320)

AstraZeneca

Biogen

CHDI Foundation

General Electric

Eli Lilly and Company

Merck

Novartis

Pfizer

Sanofi
License Information

Version of Record valid from 2017-09-01
More Information

Publication History

Published: 2017-09-01